First Time Loading...

Intercept Pharmaceuticals Inc
NASDAQ:ICPT

Watchlist Manager
Intercept Pharmaceuticals Inc Logo
Intercept Pharmaceuticals Inc
NASDAQ:ICPT
Watchlist
Price: 19 USD Market Closed
Updated: Apr 28, 2024

Intercept Pharmaceuticals Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Intercept Pharmaceuticals Inc
Revenue Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Intercept Pharmaceuticals Inc
NASDAQ:ICPT
Revenue
$317.7m
CAGR 3-Years
2%
CAGR 5-Years
14%
CAGR 10-Years
69%
Abbvie Inc
NYSE:ABBV
Revenue
$54.3B
CAGR 3-Years
6%
CAGR 5-Years
11%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$27.1B
CAGR 3-Years
3%
CAGR 5-Years
4%
CAGR 10-Years
9%
Amgen Inc
NASDAQ:AMGN
Revenue
$28.2B
CAGR 3-Years
4%
CAGR 5-Years
3%
CAGR 10-Years
4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$9.9B
CAGR 3-Years
17%
CAGR 5-Years
26%
CAGR 10-Years
23%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$13.1B
CAGR 3-Years
16%
CAGR 5-Years
14%
CAGR 10-Years
20%

Intercept Pharmaceuticals Inc
Revenue Breakdown

Breakdown by Geography
Intercept Pharmaceuticals Inc

Not Available

Breakdown by Segments
Intercept Pharmaceuticals Inc

Total Revenue: 285.7m USD
100%
Product: 285.7m USD
100%

See Also

What is Intercept Pharmaceuticals Inc's Revenue?
Revenue
317.7m USD

Based on the financial report for Sep 30, 2023, Intercept Pharmaceuticals Inc's Revenue amounts to 317.7m USD.

What is Intercept Pharmaceuticals Inc's Revenue growth rate?
Revenue CAGR 10Y
69%

Over the last year, the Revenue growth was 15%. The average annual Revenue growth rates for Intercept Pharmaceuticals Inc have been 2% over the past three years , 14% over the past five years , and 69% over the past ten years .